About
Treatment of TBI, Stroke, and Alzheimer’s Disease, and other injuries to the brain
Areas of Focus
Categories
Small Molecule PharmaceuticalBoston & New England
Team (15)
Christine Gallagher
Christine Gallagher, MBA, Director
Astrocyte Pharmaceuticals
team_member
Colonel (Ret
Colonel (Ret.) Dallas C. Hack, M.D., M.P.H., Advisor
Astrocyte Pharmaceuticals
advisor
David W
David W. Wright, M.D., Advisor
Astrocyte Pharmaceuticals
advisor
Gregory W
Gregory W. Albers, M.D., Advisor
Astrocyte Pharmaceuticals
advisor
Jackson Streeter
Jackson Streeter, M.D., Director
Astrocyte Pharmaceuticals
team_member
James D
James D. Lechleiter, Ph.D., Co-Founder and Advisor
Astrocyte Pharmaceuticals
advisorfounder
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
150
By Phase
PHASE2: 2PHASE1: 3
By Status
COMPLETED: 5
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT02217800Lead Sponsor
The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
PHASE2Completed
8 participants
Started: Nov 30, 2013 · Completed: May 31, 2016
NCT02235987Lead Sponsor
Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.
PHASE2Completed
20 participants
Started: Oct 31, 2012 · Completed: Apr 30, 2014
NCT02217839Lead Sponsor
Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173
PHASE1Completed
42 participants
Started: Apr 30, 2012
NCT02217488Lead Sponsor
Single Ascending Dose Tolerability Study of DG3173
PHASE1Completed
72 participants
Started: May 31, 2008
NCT02217826Lead Sponsor
Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173
PHASE1Completed
8 participants
Locations (1)
Headquarters
Cambridge, MA, United States
Map
Loading map...